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Abstract
Background: S-Adenosylmethionine (SAMe) is a dietary supplement used in the management of
osteoarthritis (OA) symptoms. Studies evaluating SAMe in the management of OA have been
limited to Non Steroidal Anti-inflammatory Drugs (NSAIDs) for comparison. The present study
compares the effectiveness of SAMe to a cyclooxygenase-2 (COX-2) inhibitor (celecoxib) for pain
control, functional improvement and to decrease side effects in people with osteoarthritis of the
knee.
Methods:  A randomized double-blind cross-over study, comparing SAMe (1200 mg) with
celecoxib (Celebrex 200 mg) for 16 weeks to reduce pain associated with OA of the knee. Sixty-
one adults diagnosed with OA of the knee were enrolled and 56 completed the study. Subjects
were tested for pain, functional health, mood status, isometric joint function tests, and side effects.
Results: On the first month of Phase 1, celecoxib showed significantly more reduction in pain than
SAMe (p = 0.024). By the second month of Phase 1, there was no significant difference between
both groups (p < 0.01). The duration of treatment and the interaction of duration with type of
treatment were statistically significant (ps ≤ 0.029). On most functional health measures both
groups showed a notable improvement from baseline, however no significant difference between
SAMe and celecoxib was observed. Isometric joint function tests appeared to be steadily improving
over the entire study period regardless of treatment.
Conclusion: SAMe has a slower onset of action but is as effective as celecoxib in the management
of symptoms of knee osteoarthritis. Longer studies are needed to evaluate the long-term
effectiveness of SAMe and the optimal dose to be used.
Background
Arthritis is one of the most common chronic medical con-
ditions encountered with older age, and osteoarthritis
(OA) is the most common type of arthritis, and a major
cause of disability. OA of the knee is more common than
any other joint. Symptoms include pain, stiffness, and
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decreased range of motion. Subjects often become limited
in their activities and quality of life, due to pain.
To manage the symptoms of OA, subjects and healthcare
providers often resort to multiple approaches, which
include lifestyle modifications, medications, exercise or
surgery. Non-steroidal anti-inflammatory drugs (NSAIDs)
are the mainstay medications used to manage osteoarthri-
tis pain. NSAIDs prevent inflammation and control pain
by blocking cyclooxygenase (COX-1 and COX-2 enzymes)
but their side effect profile is not always acceptable, partic-
ularly among the elderly. Each year more than 100,000
subjects are hospitalized for gastrointestinal complica-
tions of NSAIDs, and of those approximately 15% die
from these complications [1].
Newer NSAIDs, known as COX-2-inhibitors such as val-
decoxib (Bextra), celecoxib (Celebrex), and rofecoxib
(Vioxx), were introduced recently as providing similar
anti-inflammatory activity and pain relief but fewer gas-
trointestinal side effects, including a reduced risk of GI
erosion and bleeding. However, recent evidence does not
always support these claims, and a few studies have sug-
gested a possible increased risk of heart disease [2]. In
addition, subjects often lose the benefit from these medi-
cations once they are discontinued; however, OA is a pro-
gressive disease and as such requires continuous
management.
Over the last decade many dietary supplements were
introduced to the public for the management of a variety
of conditions including arthritis. Advertisement and
information about supplements targeting people with
arthritis can be found everywhere. Acupuncture, massage,
magnet therapy, and dietary supplements have been pro-
moted for the management of arthritis.
Given the limitations of the established osteoarthritis
medications/treatments, and the recent explosion of
information and interest in complementary and alterna-
tive medicine (CAM), the public has turned their atten-
tion to CAM and is exploring safer alternatives to manage
their symptoms. The recent American College of Rheuma-
tology (ACR) guidelines for treating OA included dietary
supplements, such as glucosamine sulfate, chondroitin
sulfate, and antioxidants, as well as acupuncture and mag-
nets as therapies under investigation [3]. While their final
judgment of their effectiveness is yet to be scientifically
proven, these therapies do seem to have the advantage of
showing, possible benefit with fewer side effects. S-Ade-
nosylmethionine (SAMe) is one of the dietary supple-
ments that gained popularity, and was recently reported
to be effective in the management of depression, liver dis-
ease and arthritis.
SAMe was first discovered in Italy in 1952 [4]. Soon after,
it became popular in Europe and more recently in the U.S.
SAMe is an important physiologic compound that is dis-
tributed throughout the body tissues and fluids. It is pro-
duced endogenously from methionine and adenosine
triphosphate (ATP). It is an important methyl group
donor playing an essential role in many biochemical reac-
tions involving enzymatic transmethylation. Those play
an important role in the biosynthesis of phospholipids
that are important for the integrity of cell membranes.
Despite our basic understanding of its role, the exact
mechanism of action in different disease conditions is not
well established. Oral SAMe achieves peak plasma con-
centrations (0.5 – 1 mg/L) 3 to 5 hours after ingestion of
an enteric-coated tablet (400 – 1000 mg). The half-life is
about 100 minutes, and it is excreted in urine and feces
[5].
Biochemically, SAMe is involved in three main metabolic
pathways: 1) methylation, as the principal source of
methyl groups in the body; 2) transsulfuration, SAMe
forms S-Adenosylhomocysteine (SAH) and then con-
verted to homocysteine (Hcy) which can be converted to
cystathionine then to cysteine and the sulfate (SO4)
donated to other metabolic intermediates; and 3) amino-
propylation, as SAMe plays an important role in the syn-
thesis of polyamines which can eventually form and
recycle methionine [6].
The exact mechanism of SAMe in reducing pain of OA is
not known, but evidence suggests that it may play a role
in reducing inflammation, increasing proteoglycan syn-
thesis or having an analgesic effect. Whether SAMe is a
COX-2 inhibitor is also not known. In vitro studies using
human articular chondrocytes have shown SAMe-induced
increases in proteoglycan synthesis [7] and proliferation
rates in rabbits [8]. SAMe may reduce inflammatory medi-
ators thus reducing pain. This was noted in other studies
with the reduction of Tumor Necrosis Factor (TNF)-alpha
and fibronectin RNA expression using cultured rabbit syn-
ovial cells [9].
Initial studies with SAMe used the parenteral route exclu-
sively due to the instability of the oral form. As additional
work allowed the development of a stable oral form of
SAMe, further studies tested the effectiveness of the oral
form in the management of several medical conditions
including osteoarthritis. The length of treatment differed
in each study ranging from 7 to 84 days for testing oral
preparations, 5 days for intravenous and 7 days for intra-
muscular preparations. Study designs usually imple-
mented a parallel group design and two studies used a
cross-over design [10][11]. Only one cross-over study
used an oral preparation with a 5-day washout period
[10]. The majority of studies compared SAMe to NSAIDs.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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Most studies used either 600 mg or 1200 mg of SAMe per
day. No specific explanations were provided to justify the
dose used. The overall conclusions of these studies
pointed toward an effect size in favor of SAMe compared
to placebo and equivalent to NSAIDs in reducing pain and
improving functioning.
Three reviews analyzed available studies to date
[12,13][14]. One is a meta-analysis [13], the other two
provide a general overview of the articles. All three reviews
reach similar conclusions that the results of available
studies are heterogeneous and do not allow for a firm con-
clusion about the effectiveness of SAMe in the manage-
ment of OA. However, despite this limitation the
consensus is that SAMe appears to be of equivalent effec-
tiveness to NSAIDs in reducing pain and improving func-
tional limitations, with fewer side effects. Di Padova
(1987) [15]concluded that SAMe had a slower onset of
action than NSAIDs, with equivalent results at 4 weeks.
Studies were frequently limited though, in quality of
design and implementation. Most studies were done dur-
ing the 1980's, with one study [16] in 1994. Since at that
time the majority of the studies compared SAMe to pla-
cebo or NSAIDs, there are presently no studies available
that evaluate the effectiveness or safety of SAMe versus the
new class of drugs used for OA, COX-2 inhibitors. The
objective of the present study is to assess the therapeutic
effectiveness of oral SAMe (S-adenosylmethionine), in
comparison to celecoxib (Celebrex®), to relieve pain and
improve function in adults with OA of the knee.
Methods
The present study is a prospective randomized double
blind cross-over design, of subjects with knee osteoarthri-
tis. We compared the effectiveness of 1200 mg SAMe (600
mg twice daily) with 200 mg celecoxib (Celebrex 100 mg
twice daily), to reduce pain and improve functional symp-
toms associated with OA of the knee. Each phase of the
study was for a total of 8 weeks with one-week washout
between the two phases.
Setting
The study was conducted at the General Clinical Research
Center (GCRC) in the University of California, Irvine,
Medical Center (UCIMC) from September 2000 to Sep-
tember 2002.
Selection criteria
Inclusion criteria consisted of a) adults age 40 or older,
diagnosed with OA of the knee, based on the American
College of Rheumatology criteria for the classification of
OA of the knee, i.e. knee pain morning stiffness up to 30
minutes, and crepitus on motion [17], and b) agreement
to participate in the study protocol as described in the
informed consent form. Two-view radiographs of the
knee that was most affected by OA were obtained. Exclu-
sion criteria consisted of any history of adverse reaction to
the study drugs (SAMe, celecoxib or sulfa drugs), current
pregnancy status, active infection, blood coagulopathy,
use of narcotic analgesics, acute or serious illness, uncon-
trolled hypertension, moderate to severe CHF, neurologi-
cal defects involving the lower extremity, bipolar disorder,
history of adverse reaction to anti-depressants, or current
treatment for depression.
Participants
Adults with diagnosis of OA of the knee were recruited for
this study. Sample size was calculated based on the
assumptions of a) a minimum clinically significant differ-
ence equal to 10% of the maximum VAS pain score, b) a
population standard deviation of the difference between
SAMe and celecoxib equal to 27.5% of the maximum VAS
pain score, c) a two-sided alpha level of 0.05 and d) a beta
level of 0.2 (80% power). Using the method given by
Lachin [18], 60 patients would be required.
During the open enrollment, four electronic recruitment
announcements to all employees at the University of Cal-
ifornia, Irvine, and its medical center were sent. This
resulted in 242 initial inquiries about the study with 190
telephone-screening interviews. Seventy subjects met the
inclusion /exclusion criteria and were invited to be exam-
ined by the physician. Sixty-one participants agreed and
were finally enrolled in this study.
Study design
The study was a randomized, double-blind, cross-over
trial over a 4-month period. Each phase of the study lasted
8 weeks, with one week of washout in between. The Spe-
cialty Pharmacy conducted the randomization process
after each participant met the inclusion criteria and was
enrolled in the study. Allocation to treatment groups was
concealed to participants, investigators, and research staff
until all the participants had completed the study.
Study procedure
Participants were assessed in-person during 5 visits con-
ducted at monthly intervals. Visit #1 was the baseline
assessment, visit #2 was the phase 1 midpoint assessment,
visit # 3 was the end of Phase 1 and served as baseline
assessment of Phase 2, visit #4 was at the midpoint of
phase 2, and visit #5 was at the end of phase 2, upon com-
pletion of the study. At visits #1, 3, and 5, assessments
included a review of concurrent medications, a medical
examination by a physician and a nurse; assessment of
pain, activity impairment, functional health, mood, and
knee strength and flexibility measurements. These
encounters lasted about 1.5 hours each. At visits #2 and 4,
assessments included vital signs, weight, edemaBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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measurements, a review of adverse experiences and pain.
Visits #2 and 4 lasted about 20 minutes each.
During each visit, participants were provided with a calen-
dar page to serve as a health diary for the upcoming
month. Participants were asked to note any changes in
their health and any additional medication they used for
their knee pain. Participants were advised, when possible,
to use only acetaminophen (Tylenol) for breakthrough
knee pain. When stronger pain medicine was needed, they
were asked to note this on their health calendar.
Each participant received a $100 honorarium at the end of
the study to cover travel expenses for five visits.
Intervention
Participants were randomly assigned to one of two
sequences: Sequence A received SAMe 600 mg bid for 8
weeks in Phase 1, followed by celecoxib (Celebrex) 100
mg bid for 8 weeks in Phase 2. Sequence B received
celecoxib for 8 weeks in Phase 1, followed by SAMe for 8
weeks in Phase 2. One week of washout was allowed prior
to dispensing each of the study medicines.
SAMe is biologically synthesized from L-methionine and
adenosine triphosphate (ATP) mediated by the enzyme
adenosylmethionine synthetase (formally known as
methionine adenosyltransferase or MAT) [4]. The SAMe
(S-adenosyl-L-methionine disulfate monotosylate salt)
used in our study contained 45% S/S and 55% R/S isomer
or a ratio of 45%/55%. The S/S or R/S indicates the chiral-
ity of the amino acid molecule where the first letter refers
to the confirmation at the sulfur atom and the second let-
ter refers to the confirmation at the alpha-carbon. A stere-
ospecific colorimetric assay has been shown to identify
these isomers [19]. The S-Adenosyl-L-Methionine (SAMe)
used in this study was enteric coated 200 mg tablets from
400 mg S-Adenosyl-L-Methionine Disulfate Monotosylate
salt, the "elemental" amount of SAMe in the salt mixture
is 540 mg. The SAMe was verified for quality assurance
and potency using a high pressure liquid chromatography
(HPLC) analysis with a reference standard of S-adenosyl-
methionine p-tolunenesulfonate salt (Sigma Lot
77H7053). Results of analysis yielded 99% of relative
label claim with <0.005% relative % of degradation
product.
Celecoxib was of pharmaceutical grade quality, available
to pharmacies all over the United States. The Research
Pharmacy produced "Dummy" placebo capsules and tab-
lets, as celecoxib is marketed in capsules and SAMe in tab-
lets. The SAMe and celecoxib (Celebrex) medications were
stored under refrigeration in the research pharmacy, pro-
tected from heat and light. Medications were labeled to
meet state dispensing requirements and were dispensed in
a double-blind, double-dummy randomized design.
Main Outcome Measures
Pain
A visual analog scale [20] was administered at visits #
1,2,3,4, 5, with four-week intervals between visits. One
scale ascertained pain "today" and a second scale meas-
ured pain "in the past month".
Activity impairment
A 24-item questionnaire, adapted from the Rowland-Mor-
ris activity scale [21], was administered at visits # 1,3, and
5.
Functional health
Perceived functional activities were measured with the
COOP questionnaire [22], addressing level of physical fit-
ness, emotional distress, daily work, social activity, pain,
change in health, overall health, social support, and qual-
ity of life. All nine items used pictorial representations and
brief descriptions of the five levels of intensity. The COOP
questionnaire has been shown to be reliable and valid
[23]. The questionnaire was administered at visits # 1, 3,
and 5.
Functional health was measured with a widely used
health survey, the MOS SF-36 [24]. The SF-36 scales
include physical functioning, role limitation due to phys-
ical health, role limitation due to emotional problems,
vitality, mental health, social function, bodily pain, and
general health. The SF-36 has been shown to be reliable
and valid [23]. The questionnaire was administered at vis-
its # 1, 3, and 5. Both instruments have been shown to
have good concurrent validity.
Mood status
Depression was measured with the short form of the Ger-
iatric Depression Scale [25], comprising 15 yes/no ques-
tions. The questionnaire was administered at visits # 1, 3,
and 5.
Clinical assessment of OA of the knee
A physician, blinded to the participant's randomzation
followed the Western Ontario Mac Master (WOMAC) pro-
tocol [26] at visits # 1,3, and 5. Three residents from the
Department of Physical Medicine & Rehabilitation,
trained to conduct the protocol, performed clinical assess-
ments to measure tenderness, swelling, and fluid in the
knee on a 4-point scale. They measured the knee circum-
ference (in cm) at 2 cm above the superior and 2 cm
below the inferior border of the patella. They asked the
participants to indicate the frequency of mild, moderate
and severe pain and to rate pain during walking measured
on a 10-point scale. They asked participants to indicateBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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which activities of daily living they felt impaired, from a
choice of 8 activities.
Knee strength and mobility
An isokinetic multi-joint system, the Biodex System III
(Biodex Medical Systems, Shirley, NY), was used to meas-
ure isometric strength at 60 degrees (peak flexion and
peak extension); isokinetic strength at 60 degrees (peak
flexion, peak extension, average flexion, average exten-
sion); and isokinetic strength at 180 degrees (peak flexion,
peak extension, average flexion, average extension). Walk-
ing speed was timed electronically over a 5-meter
distance.
Side effects
Subjects were made aware of possible side effects during
the first visit. Adverse reactions were monitored with
health diaries, nursing assessments and clinical interviews
in-person at visits # 2, 3, 4, and 5. Subjects were also asked
to phone or e-mail about adverse symptoms.
Statistical methods
Comparisons between SAMe and celecoxib were based on
Analysis of Variance (ANOVA) with factors for treatment
(SAMe versus celecoxib), Time (Phase 1 versus Phase 2),
Sequence (SAMe-celecoxib versus celecoxib-SAMe) and
subjects within sequence. Treatment and time were
within-subject effects and Sequence was a between-sub-
jects effect. The primary analysis included only subjects
with data from both the SAMe and celecoxib phase. Addi-
tional analyses were performed on all available data using
the Generalized Estimating Equation (GEE) method to
handle missing data.
For pain scores (measured at the middle as well as the end
of each treatment period) effects of time on each treat-
ment were analyzed using a within subject factorial
ANOVA with effects of treatment (SAMe versus
Celecoxib), time on the treatment (Month 1 versus Month
2) and the interaction of treatment with time on each
treatment.
Comparisons between the two sequence groups at differ-
ent time periods were performed using Student's t test.
Comparisons of post-treatment results with baseline were
performed using the paired t test. Comparisons of the
incidence of adverse events used the exact binomial test
for within-subject comparisons and the Fisher exact test
for between-subject comparisons.
Analyses of possible effects of SAMe deterioration on pain
scores were analyzed assuming a negative exponential
decay function and performing an ANOVA with factors
for time on the treatment (Month 1 versus Month 2) and
the calculated dose of SAMe.
Statistical comparisons were based on all matched pairs
data or on all available data as appropriate. Sample sizes
may be lower than the total number of subjects if data
were missing. Two-sided p values are reported.
Equivalence tests were performed on pain measures using
the Two One-Sided Tests (TOST) procedure [27]. For
assessment of equivalence, the minimum clinically signif-
icant difference was defined as 10 percent of the maxi-
mum VAS pain score. The 90% confidence intervals were
determined using the standard error of the difference




A total of 61 subjects met the inclusion criteria and were
entered in this study (Table 1). After completing the initial
assessment, subjects were randomly assigned to sequence
A or B. Thirty subjects were randomized to sequence A
(SAMe followed by celecoxib) and 31 subjects into
sequence B (celecoxib followed by SAMe).
Demographics and Baseline Data
There were no significant demographic differences
between subjects assigned to sequence A and those
assigned to Sequence B (ps > 0.10) (Table 2). Subjects in
this study tended to be obese, as indicated by an average
body mass index greater than 30.
Table 1: Treatment assignment and compliance.
Sequence A SAMe – Celecoxib Sequence B Celecoxib – SAMe
Subjects Randomized to each arm 30 31
PHASE 1 SAMe Celecoxib
Subjects receiving treatment 29 30
Subjects Completing Phase 1 28 29
PHASE 2 Celecoxib SAMe
Subjects receiving treatment 28 29
Subjects Completing Phase 2 27 29BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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Sequence A (SAMe-celecoxib) comprised 30 participants
assigned at random, 28 completed Phase 1 of the protocol
and 27 completed Phase 2. Twenty-seven participants
were analyzed for the primary outcome. Sequence B
(celecoxib-SAMe) comprised 31 participants assigned at
random, 29 completed Phase 1 of the protocol and 29
completed Phase 2. Twenty-nine participants were ana-
lyzed for the primary outcome. Three subjects discontin-
ued participation in Sequence A and two in Sequence B. In
each sequence, one subject withdrew during the washout
period and one during the celecoxib treatment. During
the washout period, the reasons for withdrawal were:
insufficient pain to warrant treatment and stroke. During
the celecoxib treatment, reasons for withdrawal were: one
subject did not reply to follow-up scheduling, and one
was diagnosed with rheumatoid arthritis 4 weeks into the
treatment. During the SAMe treatment one patient with-
drew after 3 days due to headache.
Pain Based on the VAS Scale
Pain was assessed on two separate visual analog scales. For
the first scale, subjects were asked to rate pain today. For
the second scale, subjects were asked to rate pain over the
past month. Analyses of results from the two measures are
similar. In Phase 1, at the end of the first month, the
celecoxib group showed significant reductions from base-
line (ps < 0.01), while the reductions of pain in the SAMe
group were only marginal (ps < 0.10). Celecoxib showed
significantly more reduction in pain than SAMe during
the first month of treatment (p = 0.024). By the second
month of Phase 1, both groups were significantly
improved from baseline (ps < 0.01) and there was no sig-
nificant difference between them.
In Phase 2, during the first month, the group that switched
from celecoxib to SAMe was noticeably but not signifi-
cantly worse than the group that shifted from SAMe to
celecoxib. However, by the end of Phase 2, there was no
apparent difference between the two groups.
Despite these minor differences, the overall results from
the two measures on pain in both groups are similar (See
Figure 1).
Because the effects of SAMe and celecoxib seem unaffected
by the order of treatment, it is reasonable to combine
results from Phase 1 and Phase 2. Cross-over analyses
indicated that celecoxib was significantly better at Month
1 (ps ≤ 0.023) but there was no significant difference
between the two groups at Month 2. There were no signif-
icant effects of time (Phase 1 versus Phase 2) or sequence
(A versus B). The analysis combining Month 1 and Month
2 data showed significant effects of treatment for pain
over the past month (p = 0.043) but not for pain today (p
= 0.247). For both pain measures, the effects of duration
of treatment and the interaction of duration with type of
treatment were statistically significant (ps ≤ 0.029) indi-
cating that the patterns shown in Figures 1-4 are reliable.
The mean difference between the two groups (SAMe
minus Celecoxib) on the "pain today" measure was 9.3 at
the end of Month 1 and -0.4 at the end of month 2. The
difference score on the "pain over the past month" meas-
Table 2: Demographics and baseline variables.
Variable Sequence A SAMe – Celecoxib (N = 28) Sequence B Celecoxib – SAMe (N = 29)
Mean (SD) Mean (SD)
Age (years) 51.6 (9.7) 54.1 (10.1)
Height (in) 66.4 (3.9) 66.4 (3.5)
Weight (lbs) 192.3 (38.1) 200.2 (37.8)
Body Mass Index (kg/m2) 30.7 (5.8) 32.1 (6.5)
N (%) N (%)
Females 20 (71.4%) 20 (69.0%)
Males 8 (28.6%) 9 (31.0%)
White 21 (75.0%) 21 (72.4%)
Hispanic 5 (17.9%) 5 (17.2%)
Asian 0 (0.0%) 2 (6.9%)
Black 1 (3.6%) 1 (3.4%)
Native American 1 (3.6%) 0 (0.0%)
There was no statistically significant difference between the two sequencesBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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ure was 11.6 at the end of Month 1 and 1.6 at the end of
Month 2. The 90% confidence intervals for the "pain
today" measure were 2.7 to 15.8 at the end of Month 1
and -7.4 to 6.6 at the end of Month 2. The 90% confidence
intervals for the "pain over the past month" measure were
5.2 to 18.1 at the end of Month 1 and -6.1 to 9.3 at the end
of Month 2. Thus, regardless of the pain measure used,
equivalence (based on a minimum clinically significant
difference of 10) was demonstrated at the end of Month 2
but not at the end of Month 1 (Figure 2).
COOP Scores
COOP scores are shown in Table 3. ANOVA showed no
significant difference between SAMe and celecoxib on any
measure. Effects of time (Phase 1 versus Phase 2) and
sequence were also non significant. Both groups showed a
significant improvement from baseline in the total COOP
score as well as [work], [pain], [change in health] and
[overall health]. Neither group showed a significant
change from baseline in [physical fitness], [emotional]
and [daily activity]. On the [social support] and [quality
of life] measures, the SAMe group showed a significant
improvement from baseline (ps ≤ 0.018) while the
celecoxib group did not.
SF-36 Scores
SF-36 scores are shown in Table 4. ANOVA showed no sig-
nificant difference between SAMe and celecoxib on any
measure. There was a significant effect of time (Phase 1
versus Phase 2) on the vitality measure (p = 0.024) but,
otherwise, there were no significant time or sequence
effects. Both groups showed a significant improvement
from baseline on the physical function, role physical,
bodily pain, and general physical measures (ps ≤ 0.045).
Mean VAS pain scores (based on the "pain today" measure) in the two treatment sequence groups. Figure 1
Mean VAS pain scores (based on the "pain today" measure) in the two treatment sequence groups. In both sequence groups, 
SAMe was associated with higher pain scores during the first month of treatment but this effect disappeared after two months 
of treatment.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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Neither group showed a significant change from baseline
on the role emotional, mental health, social function,
general health or general mental measures. The vitality
measure showed a significant improvement for the
celecoxib group (p = 0.012) but the magnitude of this
effect was quite small.
WOMAC, Activity and Mood
WOMAC scores, Roland-Morris activity scores and Mood
scores are shown in Table 5. The only measure that
showed any difference between SAMe and celecoxib was
circumference of the knee measured in centimeters (cm).
The subjects receiving Sequence A showed a decrease from
baseline of 0.3 cm in the first (SAMe) phase and an
increase from baseline of 0.2 cm during the second
(celecoxib) phase. The subjects receiving Sequence B
showed an increase from baseline of 0.3 cm in the first
(celecoxib) phase and no change from baseline in the sec-
ond (SAMe) phase. This difference was statistically signif-
icant (p = 0.001). Curiously, the measures of swelling in
the knee and fluid in the knee showed no such trend. The
Roland-Morris activity score and the frequency of at least
moderate pain showed significant time (Phase 1 versus
Phase 2) effects (ps ≤ 0.035) but, otherwise, there were no
significant time or sequence effects. Both groups showed
significant improvement in tenderness in the knee, swell-
ing in the knee, pain during walking, pain frequency,
ADL, the Roland-Morris activity score and the mood score
(ps ≤ 0.037). Neither group showed significant changes
from baseline in circumference of the knee or swelling of
the knee.
Mean VAS pain scores (based on the "pain today" measure) with standard errors of the mean as a function of treatment with  SAMe or Celecoxib. Figure 2
Mean VAS pain scores (based on the "pain today" measure) with standard errors of the mean as a function of treatment with 
SAMe or Celecoxib.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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Biodex
Biodex data are shown in Tables 6 &8. All of the measures
showed significant improvement from baseline (ps ≤
0.001) and most of them showed significant time effects
(Phase 1 versus Phase 2) in the overall ANOVA. These
measures appeared to be steadily improving over the
entire study period regardless of treatment. However,
there was no significant difference between SAMe and
celecoxib.
Adverse Events
Thirty-six subjects reported adverse events during the
SAMe period and 46 subjects reported adverse events dur-
ing the celecoxib period. The most common adverse
Table 3: Baseline measures of osteoarthritis and related impairment.
Variable Sequence A SAMe – Celecoxib (N = 28) Sequence B Celecoxib – SAMe (N = 29)
N (%) N (%)
Tenderness in Knee*
None 5 (18.5%) 6 (20.7%)
Slight 9 (33.3%) 7 (24.1%)
Moderate 13 (48.1%) 14 (48.3%)
Severe 0 (0.0%) 2 (6.9%)
Swelling in Knee*
None 15 (55.6%) 6 (20.7%)
Slight 10 (37.0%) 17 (58.6%)
Moderate 2 (7.4%) 6 (20.7%)
Fluid in Knee Joint*
None 22 (81.5%) 20 (69.0%)
Slight 3 (11.1%) 7 (24.1%)
Moderate 2 (7.4%) 2 (6.9%)
Redness in Knee* 0 (0.0%) 1 (3.4%)
Walking Distance**
<1 block without pain 3 (10.7%) 3 (10.3%)
<1 block with pain 1 (3.6%) 4 (13.8%)
<1 mile without pain 1 (3.6%) 1 (3.4%)
<1 mile with pain 6 (21.4%) 7 (24.1%)
>1 mile without pain 6 (21.4%) 4 (13.8%)
>1 mile with pain 12 (42.9%) 13 (44.8%)
Basic ADL – Need Assistance with
Dressing 1 (3.6%) 0 (0.0%)
Transferring 0 (0.0%) 0 (0.0%)
Bathing 0 (0.0%) 0 (0.0%)
Toileting 0 (0.0%) 0 (0.0%)
Advanced ADL – Difficulty with
Light housework 1 (3.6%) 4 (13.8%)
Heavy housework 9 (32.1%) 16 (55.2%)
Stooping / crouching 26 (92.9%) 27 (93.1%)
Getting in/out of car 17 (60.7%) 18 (62.1%)
* One patient in Sequence A had missing data. ** Multiple responses per patient were allowed. There were no statistically significant differences 
between the two sequences.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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events were gastrointestinal disorder (SAMe 4: celecoxib:
6, NS), anxiety (SAMe: 5, celecoxib 4, NS) and dyspepsia
(SAMe: 1, celecoxib: 3, NS). No other adverse event was
reported by more than two subjects. One patient termi-
nated the study due to headache three days into the SAMe
treatment; however this patient had a well known history
of such headaches prior to enrolling in the study.
Loss of SAMe potency
The increased incidence of pain in the SAMe group was
concentrated in the first month of Phase 2 where 12 of 29
subjects who had recently switched from celecoxib to
SAMe complained of pain, while only 2 of 24 subjects
recently switched from SAMe to celecoxib complained of
pain (p = 0.011). The difference between groups was not
statistically significant at any other time period.
Approximately 75% of the way through the study, a rou-
tine quality check of a random sample of the study medi-
cine indicated that the SAMe had lost approximately 51%
of its potency. At this time, the study was delayed until a
new batch of SAMe could be obtained. In order to exam-
ine this effect, potency was crudely estimated based on the
assumption of an exponential decay curve from 100%
potency at the start of the study to 49% potency at day
595. This yields the equation y = exp (-0.0011989x) where
y is potency and x is days from the start of the study or
days from the starting time for the new batch of SAMe. An
ANOVA on pain-today scores in SAMe treated subjects
Table 4: Pain scores (pain was scored on a visual analog scale where 0 = no pain and 100 = the highest possible pain level).
Baseline SAMe Celecoxib
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif
Pain Level Today
Month 1 52 45.3 (23.8) 33.8* (24.0) 24.6* (23.9) -0.33*
Month 2 52 46.1 (24.2) 24.0* (19.5) 24.4* (23.6) 0.01
Pain Level over the Past Month
Month 1 52 56.7 (22.5) 44.1* (22.4) 32.5* (24.0) -0.42**
Month 2 52 57.0 (23.4) 34.7* (22.7) 33.1* (22.8) -0.05
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample size is less than 57 due to missing data in 
either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). ** Difference between SAMe and 
Celecoxib is statistically significant (p < 0.05).
Table 5: COOP scores.
Baseline SAMe Celecoxib
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
Total Score 46 48.7 (8.7) 39.9* (9.3) 39.8* (11.3) -0.01
Physical Condition 46 56.2 (20.4) 51.7 (19.1) 51.3 (18.2) -0.02
Emotional Condition 46 37.6 (16.1) 33.5 (17.9) 34.8 (17.6) 0.07
Daily Work 46 47.1 (17.0) 34.3* (14.4) 33.9* (15.7) -0.03
Social Activities 46 31.4 (15.4) 29.1 (13.1) 29.6 (15.6) 0.02
Pain 46 70.5 (14.1) 53.0* (15.9) 50.9* (19.2) -0.10
Change in Condition 46 65.2 (13.3) 49.1* (16.7) 47.8* (18.6) -0.05
Overall Condition 46 50.0 (16.1) 44.3* (16.3) 41.3* (16.0) -0.19
Social Support 46 39.0 (24.6) 29.6* (18.3) 32.6 (18.1) 0.17
Quality of Life 46 41.0 (13.9) 34.3* (16.1) 36.1 (13.1) 0.11
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe +Sample sizes are less than 57 due to missing data in 
either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences 
were observed between SAMe and CelecoxibBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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with a factor for duration of treatment (1 month versus 2
months) and a continuous potency factor produced a sig-
nificant effect of month showing improvement from
Month 1 to Month 2 (p < 0.001). The effect of SAMe
potency was in the expected direction (lower estimated
potency was correlated with higher pain) but the effect
was not statistically significant (p = 0.188).
Discussion
To our knowledge this is the first study comparing the
effectiveness of SAMe to a COX-2 inhibitor in the manage-
ment of osteoarthritis symptoms. Recent studies have
demonstrated that COX-2 inhibitors have equivalent
effectiveness but a better safety profile than other NSAIDs
in the management of osteoarthritis. Their advantage is
that by avoiding the COX-1 inhibitors they would have
less tendency to produce gastrointestinal side effects. Pub-
lished studies compared SAMe most commonly to 1200
mg of ibuprofen. Despite its efficacy at 1200 mg, ibupro-
fen is more frequently dispensed at 1600 mg/day, or
higher, based on the underlying conditions. To avoid any
doubt or controversy, we opted to use the most frequently
used dose of SAMe and the optimal dose of celecoxib.
Future studies should explore different doses of SAMe, to
identify the lowest most effective and safest dose to be
used.
Our results indicate that SAMe is equivalent in almost all
measures to COX-2 inhibitors (celecoxib) in relieving
pain and improving function in subjects with osteoarthri-
tis of the knee. It is clear from our results that SAMe has a
slower onset of action, requiring almost one month of
treatment prior to achieving similar effect to celecoxib.
COX-2 inhibitors and NSAIDs have a definite advantage
during the first month of treatment. This is consistent
with prior conclusions by di Padova [15]. However, it
does not clearly explain findings of several previously
published small studies [28][29][30][31]. These studies
although limited to 1 month of duration, reported equiv-
alent effectiveness to NSAIDs in relieving symptoms of
OA.
During the second month of each phase of the study, the
pain relieving effect is equivalent for both drugs. Of inter-
est is that, while the pain relief of celecoxib was constant
throughout the study, the effect of SAMe continued to
increase with time (Figure 1). This raises the question
whether the effect of SAMe would have continued to
improve had the study been for a longer period of time?
Hence a more extended study is needed to evaluate the
long-term effect of SAMe and to assess the presence of a
possible ceiling effect of this supplement. Another possi-
ble interpretation could be that the effect of SAMe slows
the progression of the disease, hence the persistent effect
after discontinuation. The same effect was not seen with
celecoxib.
Although this study was not set up to evaluate the long-
term effect of SAMe, the data hints that the pain relief
effect obtained with SAMe persisted even after the medi-
cation was discontinued (Figure 1). In this study we noted
that subjects who changed from SAMe to celecoxib had an
initial decline in their pain level, however the level was
back to baseline at 2 months consistent with the level of
those that were started on celecoxib. Although the differ-
ence was not statistically different in both groups, this ini-
tial dip beyond the baseline pain relief obtained by
celecoxib alone hint for a possible persistent effect of
SAMe for 1 month beyond discontinuation of the medica-
tion. This is reminiscent of reports on the pain relieving
Table 6: SF-36 scores (higher scores indicate less impairment).
Baseline SAMe Celecoxib
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
Physical Function 53 52.5 (20.8) 62.4* (22.8) 63.7* (25.1) -0.10
Role Physical 53 56.6 (37.4) 66.5* (33.6) 67.9* (38.1) -0.04
Role Emotional 53 86.8 (29.5) 88.7 (24.4) 87.4 (27.1) 0.06
Vitality 53 58.9 (14.4) 60.4 (14.0) 62.9* (14.5) -0.23
Mental Health 53 71.8 (11.4) 73.7 (11.3) 74.0 (11.8) -0.03
Social Function 53 82.3 (20.1) 84.2 (19.8) 86.3 (18.7) -0.09
Bodily Pain 53 46.8 (14.1) 59.3* (19.8) 63.1* (19.6) -0.16
General Health 53 74.6 (15.2) 75.4 (17.2) 76.6 (16.8) -0.10
General Physical 53 38.1 (8.2) 42.3* (9.5) 43.4* (10.6) -0.16
General Mental 53 54.6 (7.8) 54.1 (7.4) 54.2 (6.8) -0.02
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in 
either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences 
were observed between SAMe and Celecoxib.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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effect observed with glucosamine sulfate. If this result
could be reproduced in future large studies, the question
will be raised of whether SAMe could be used as a pulsed
therapy, for the management of pain in OA, after an initial
period to establish a steady level?
Functional health
Several health measures were assessed during this study,
including medical and joint function assessments, meas-
ures of daily function and activity impairment, assess-
ments of mood and quality of life. On most of these
measures, both treatment groups showed significant
improvements from baseline and isometric joint function
tests appeared to be steadily improving over the entire
study period as well, regardless of treatment. No statisti-
cally significant difference was seen between SAMe and
celecoxib. Thus, the evidence of comparable efficacy
between SAMe and celecoxib seems rather solid.
Of interest but of unclear clinical significance is the meas-
urement of the knee circumference. The circumference dif-
fered significantly between the two treatments, with a
decrease from baseline of 0.3 cm during the SAMe phase
and an increase from baseline of 0.2 cm during the
celecoxib phase. While this statistical difference does not
seem to have much clinical meaning, future studies on the
mechanism of action of SAMe might shed light on this
decrease in knee circumference.
Perceived physical fitness, emotional well-being and daily
activities did not improve from baseline with either treat-
ment. Fitness and well-being as well as daily activities
might represent more stable attributes than physical com-
plaints and thus might not change in a 2-months
treatment.
Depression
Of interest is that no participant in this study was identi-
fied with depression, using the abbreviated geriatric
depression scale, during this study. Hence the results and
discussion of effects of SAMe on depression in this study
Table 7: WOMAC, activity and mood scores (higher scores indicate more impairment: scaled from 0 to 100 except for knee 
circumference).
Baseline SAMe Celecoxib
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
WOMAC Knee Assessment
Tenderness 50 29.9 (21.8) 14.7* (17.4) 19.3* (18.9) 0.21
Swelling 51 15.7 (15.6) 9.8* (14.6) 8.2* (12.2) -0.11
Fluid 49 6.6 (14.1) 6.8 (14.8) 4.4 (10.1) -0.14
Knee Circumference (cm)
Total 50 41.6 (4.8) 41.5 (4.7) 42.1 (5.0) 0.52**
Above patella 50 45.0 (6.0) 44.8 (5.7) 45.4 (5.7) 0.43**
Below patella 50 38.3 (3.7) 38.2 (3.8) 38.9* (4.5) 0.40**
WOMAC Pain Frequency
Mild 49 73.3 (27.9) 57.1* (28.4) 61.2* (27.0) 0.12
Moderate 46 65.6 (19.4) 46.2* (25.8) 38.6* (24.6) -0.24
Severe 46 45.7 (20.8) 26.6* (22.6) 22.8* (24.1) -0.14
WOMAC Other
Pain – Walking 25 37.8 (31.3) 17.6* (20.5) 19.2* (22.7) 0.07
ADL 50 26.0 (13.0) 20.3* (14.2) 17.8* (15.2) -0.19
Activity Score 53 55.6 (24.3) 37.0* (27.4) 34.8* (30.0) -0.10
Mood Score 52 13.2 (14.8) 8.6* (11.8) 9.9* (12.2) 0.17
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in 
either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). ** Difference between SAMe and 
Celecoxib is statistically significant (p < 0.05).BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
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should be interpreted with caution and could not be gen-
eralized to a depressed population.
Despite a slight drop in the mood scale while subjects
were on SAMe (see Table 7), no statistical difference in the
depression scale was noted while subjects were on SAMe
during this study. However, one conclusion remains clear,
given the absence of positive antidepressive effects seen in
this study, one can conclude that the beneficial results
(pain, function) noted in this study could not be
explained by the antidepressive effect of SAMe. Hence
other mechanisms of action are in effect, and further stud-
ies are warranted to explore these mechanism.
Adverse events
The type of side effects seen in this study is consistent with
those reported in other trials. Gastrointestinal, psychiat-
ric, insomnia, allergy, and rash were all reported in previ-
ous studies. Again consistent with prior data,
gastrointestinal and psychiatric side effects were the most
common. This is consistent with findings by Soeken et al.
[13] that subjects on SAMe were less likely to experience
side effects than those treated with NSAIDs. In her
analysis, Soeken reports that this is independent of SAMe
dose or length of intervention.
Of note is that the most common reported complaint in
this study, although not included under adverse event, is
pain. This could be attributed to either failure of the med-
ication to provide adequate pain relief (SAMe during the
first weeks of therapy); or for this study during the period
where the potency of SAMe tablets was initially noted to
have declined.
Potency and quality assurance
SAMe is produced biologically in the S/S form. Both R/S
and S/S isomers are biologically active [32]. Under nor-
mal physiological conditions or normal storage condi-
tions, SAMe spontaneously racemizes to form a mixture of
S and R isomers, thus over time, the S/S form converts into
the R/S form. This is an equilibration phenomenon and
occurs in the commercial form. The racemisation at the
sulfur side of the SAMe molecule has been established in
the literature [33]. All commercial SAMe products are
manufactured by combining fermentation and synthetic
steps. Commercially available SAMe has been tested to
have different ratios of S/S & R/S isomers ranging from
70%/30% to 45%/55% (unpublished data). Several
studies have indicated that the S/S-SAMe configuration is
the "active" form involved in methyltransferase catalyzed
reactions [34]'[35]'[36] and that the R/S-SAMe configura-
tion is the biologically "inactive" form as it may inhibit
methyltransferases reactions [37]. In more of a functional
Table 8: Biodex data (except for walking speed, higher scores indicate less impairment).
Baseline SAMe Celecoxib
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
Isometric 60 degrees
Peak flexion 45 66.7 (30.6) 80.2* (30.0) 77.5* (29.2) 0.21
Peak extension 45 92.4 (40.8) 116.6* (52.0) 112.5* (50.3) 0.19
Isokinetic 60 degrees
Peak flexion 45 40.5 (21.2) 54.8* (26.5) 52.3* (20.9) 0.16
Peak extension 45 84.2 (43.5) 107.1* (43.0) 102.4* (39.0) 0.24
Average flexion 45 22.2 (16.8) 32.1* (18.4) 29.9* (15.2) 0.19
Average extension 45 48.0 (27.5) 64.3* (28.3) 62.3* (26.4) 0.14
Isokinetic 180 degrees
Peak flexion 45 30.7 (15.7) 39.0* (16.3) 37.9* (15.1) 0.13
Peak extension 45 57.0 (29.5) 72.3* (31.0) 69.3* (28.0) 0.19
Average flexion 45 25.3 (27.8) 42.7* (32.4) 39.3* (29.3) 0.18
Average extension 45 76.5 (53.0) 109.6* (56.4) 105.6* (50.9) 0.14
Walking Speed 42 3.12 (1.52) 2.63* (0.91) 2.56* (0.69) -0.14
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in 
either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences 
were observed between SAMe and Celecoxib.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/6
Page 14 of 15
(page number not for citation purposes)
outcome, other authors have shown that both S/S and R/
S isomers have significant activity respectively in increas-
ing blood flow and bile production in isolated perfused
rat livers [38]. Therefore, there may not appear to be any
difference in the biological effects of the different ratios of
SAMe.
In this study, we did not perform analysis of the S/S & S/
R isomers during quality assurance. Hence we are unable
to verify whether formulations with higher or lower S/S or
S/R isomers are more potent in the management of OA.
Our experience highlights the need for future studies,
involving dietary supplements, to develop a quality assur-
ance safeguard.
Given the absence of clear and well established explana-
tion for the mechanism of action for SAMe in the manage-
ment of OA, future studies should explore the possible
role of isomers.
Limitations of the study
Although this study had fewer patients than originally
proposed, it retained sufficient power to conclude that a)
celecoxib is significantly better than SAMe in the first
month of treatment and b) by the second month of treat-
ment, SAMe and celecoxib were clinically equivalent
based on the proposed equivalence criterion.
Findings should be interpreted with caution due to the
small number of participants and the short duration of
the study. Toward the end of the study, SAMe lost about
half of its potency and the study was delayed until a new
supply of SAMe was obtained. While the lower potency
was associated with higher pain, this effect was non-signif-
icant and did not affect the overall study outcome. Future
long-term studies evaluating dietary supplements should
implement quality checks at appropriate time intervals for
adequate quality assurance.
Conclusion
SAMe is helpful for the management of pain in osteoar-
thritis, and demonstrates similar effectiveness as a cur-
rently accepted COX-2 inhibitor celecoxib. Results from
this study add and confirm results from prior studies indi-
cating a possible role for SAMe in the management of
osteoarthritis. It is clear however, that many questions
remain unanswered. Prime among these questions is:
What is the optimal (effective and safe) dose SAMe in the
management of osteoarthritis? Other question that
should be explored are: What is the long-term
effectiveness and safety of SAMe? What is the mechanism
of action of SAMe? Does SAMe effect the disease progres-
sion or could it reverse the disease process? and finally Is
the combination of SAMe and a COX-2 inhibitor more
effective than either alone in the management of osteoar-
thritis? Most of the currently available studies offer a
promise, however well done randomized controlled trials
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